Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study

Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study

Abstract Hormone receptor (HR) positive (HR +) and human epidermal growth factor receptor 2 (HER2) negative (aka HER2 −) breast cancer (BC) is the most frequently diagnosed subtype. Recent development of next-generation endocrine therapies (e.g. selective estrogen receptor degraders (SERDs); third-g...

Full description

Saved in:
Bibliographic Details
Main Authors: Grazia Arpino, Carmine De Angelis, Lorenzo Gerratana, Matteo Lambertini, Sarah Igidbashian, Rosanna Gramigna, Xavier Guillaume
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Adverse events
Metastatic HR positive/HER2 negative breast cancer
Stakeholder preferences
Treatment administration
Treatment choice
Online Access:https://doi.org/10.1186/s12885-025-14308-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14308-4

Similar Items